98%
921
2 minutes
20
Gamma knife radiosurgery (GRKS) is widely used for patients with brain metastases; however, predictions of overall survival (OS) within 3-months post-GKRS remain imprecise. Specifically, more than 10% of non-small cell lung cancer (NSCLC) patients died within 8 weeks of post-GKRS, indicating potential overtreatment. This study aims to predict OS within 3-months post-GKRS using machine learning algorithms, and to identify prognostic features in NSCLC patients. We selected 120 NSCLC patients who underwent GKRS at Chungbuk National University Hospital. They were randomly assigned to training group (n = 80) and testing group (n = 40) with 14 features considered. We used 3 machine learning (ML) algorithms (Decision tree, Random forest, and Boosted tree classifier) to predict OS within 3-months for NSCLC patients. And we extracted important features and permutation features. Data validation was verified by physician and medical physicist. The accuracy of the ML algorithms for predicting OS within 3-months was 77.5% for the decision tree, 72.5% for the random forest, and 70% for the boosted tree classifier. The important features commonly showed age, receiving chemotherapy, and pretreatment each algorithm. Additionally, the permutation features commonly showed tumor volume (>10 cc) and age as critical factors each algorithm. The decision tree algorithm exhibited the highest accuracy. Analysis of the decision tree visualized data revealed that patients aged (>71 years) with tumor volume (>10 cc) were increased risk of mortality within 3-months. The findings suggest that ML algorithms can effectively predict OS within 3-months and identify crucial features in NSCLC patients. For NSCLC patients with poor prognoses, old age, and large tumor volumes, GKRS may not be a desirable treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10843515 | PMC |
http://dx.doi.org/10.1097/MD.0000000000037084 | DOI Listing |
J Thorac Oncol
September 2025
Thoracic Surgery Unit, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy; Tumor Immunology and Immunotherapy Unit, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy. Electronic address:
ESMO Open
September 2025
Academic Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy.
Background: Immunotherapy has rapidly changed the treatment of early-stage non-small-cell lung cancer (NSCLC) in recent years. We aimed to summarize available evidence on the use of immunotherapy in neoadjuvant/perioperative and adjuvant settings for resectable NSCLC and explore some controversial subgroups.
Materials And Methods: Systematic literature research was carried out for randomized controlled trials of neoadjuvant/perioperative chemo-immunotherapy or adjuvant immunotherapy for resectable NSCLC.
Clin Exp Metastasis
September 2025
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan City, 250117, China.
Med Dosim
September 2025
Department of Radiological Technology, Faculty of Health Science, Juntendo University, Tokyo, 113-0034, Japan.
This study investigated hybrid volumetric-modulated arc therapy (H-VMAT) for the treatment of nonsmall cell lung cancer (NSCLC) by classifying patients based on the tumor location (left or right and upper, middle or low) and planning target volume (PTV) (less than average or greater than average) to determine the optimal VMAT dose ratio by dividing the prescription dose used for H-VMAT planning. The following treatment plans comprising four-field conformal irradiation were created for 51 patients with NSCLC: VMAT with one full arc (f-VMAT); VMAT with two partial arcs (p-VMAT); and hybrid plans. Hybrid plans comprised a combination of f-VMAT and three-dimensional conformal radiation therapy (3D-CRT; fH-VAMT) as well as a combination of p-VMAT and 3D-CRT (pH-VMAT).
View Article and Find Full Text PDFClin Lung Cancer
July 2025
Fox Chase Cancer Center, Temple Health, Philadelphia, PA. Electronic address:
Objective: This study examined brain metastases among patients with metastatic non-small cell lung cancer (mNSCLC), characterizing prevalence, use of brain imaging, and treatment patterns.
Methods: Surveillance, Epidemiology, and End Results (SEER) data linked to Medicare claims were used to examine the prevalence of brain imaging at diagnosis among Medicare beneficiaries with mNSCLC (2015-2019, inclusive of follow-up). Predictors of receipt of brain imaging and first-line systemic treatment were evaluated using logistic regression models.